Search results
Moderna Beats Quarterly Estimates as Cost-Cutting Pares Losses
Bloomberg· 1 day agoModerna Inc. reported a narrower first-quarter loss than Wall Street had expected, as the biotech...
Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025...
Benzinga· 1 day agoThursday, Moderna Inc MRNA reported a first-quarter EPS loss of $(3.07), down from an income of...
Moderna to seek parity for RSV shot (NASDAQ:MRNA)
Seeking Alpha· 1 day agoModerna (MRNA) stock gains as the company highlights its upcoming RSV shot, expecting the U.S. regulators to endorse it on par with rival products. Read more here.
Moderna beats estimates in Q1 2024, targets RSV vaccine launch in fall By Investing.com
Investing.com· 1 day agoModerna Inc. (NASDAQ:MRNA) reported first-quarter earnings and revenue that came ahead of analyst...
Moderna expects CDC to view its RSV vaccine as equal to rival shots
Reuters· 1 day ago, opens new tab said on Thursday it expects U.S. Center for Disease Control and Prevention (CDC)...
Moderna Inc (MRNA) (Q1 2024) Earnings Call Transcript Highlights: Navigating Challenges with ...
GuruFocus.com via Yahoo Finance· 13 hours agoRelease Date: May 02, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Moderna Inc (NASDAQ:MRNA) reported ...
Moderna (MRNA) Surpasses Market Returns: Some Facts Worth Knowing
Zacks via Yahoo Finance· 7 days agoModerna (MRNA) closed the most recent trading day at $107.97, moving +1.69% from the previous...
Moderna’s sales from its only product, the COVID-19 vaccine, fell 91% from last year
AOL· 1 day agoThe dark days of the pandemic are finally in the past for most of us—and that seems to be reflected in the earnings for Moderna, whose revenue is dependent on sales of its ...
Moderna makes several cost-cutting moves, leans into AI - Boston Business Journal
The Business Journals· 1 day agoAs Moderna Inc. works toward expanding its approved products beyond its Covid-19 vaccine, the...
Moderna’s sales from its only product, the COVID-19 vaccine, fell 91% from last year
Fortune· 23 hours agoIn the first quarter of the year, Moderna reported $167 million in sales of its only product on the market, its COVID-19 vaccine called Spikevax. The company’s first quarter ...